ALSO NOTED: Ranbaxy recalls tainted Gebapentin;BMS gets Abilify on fast track for bipolar kids;

> After discovering impurities in the pills, Ranbaxy Laboratories is recalling 73 million tablets of its epilepsy remedy Gebapentin from the U.S. market. Report

> Bristol-Myers Squibb and partner Otsuka Pharmaceutical said the FDA will fast-track their application to market the antipsychotic Abilify for use in children with bipolar disorder. Report

> India's Orchid Chemicals & Pharmaceuticals got the FDA's nod for its version of the antibiotic Cefpodoxime Proxetil, marketed by Pfizer under the brand name Vantin. Report

> Surgical instruments maker Gyrus was hit with a patent infringement suit by rival ArthroCare. Report

And Finally... Governments meet next week to hammer out a flu-virus sharing agreement so scientists can better track the evolution of H5N1. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.